Exact Mass: 465.29675740000005
Exact Mass Matches: 465.29675740000005
Found 421 metabolites which its exact mass value is equals to given mass value 465.29675740000005,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Glycocholic acid
C26H43NO6 (465.30902180000004)
Glycocholic acid is an acyl glycine and a bile acid-glycine conjugate. It is a secondary bile acid produced by the action of enzymes existing in the microbial flora of the colonic environment. Bacteroides, Bifidobacterium, Clostridium and Lactobacillus are involved in bile acid metabolism and produce glycocholic acid (PMID: 6265737; 10629797). In hepatocytes, both primary and secondary bile acids undergo amino acid conjugation at the C-24 carboxylic acid on the side chain, and almost all bile acids in the bile duct therefore exist in a glycine conjugated form (PMID: 16949895). More specifically, glycocholic acid or cholylglycine, is a crystalline bile acid involved in the emulsification of fats. It occurs as a sodium salt in the bile of mammals. Its anion is called glycocholate. As the glycine conjugate of cholic acid, this compound acts as a detergent to solubilize fats for absorption and is itself absorbed (PubChem). Bile acids are steroid acids found predominantly in bile of mammals. The distinction between different bile acids is minute, depends only on presence or absence of hydroxyl groups on positions 3, 7, and 12. Bile acids are physiological detergents that facilitate excretion, absorption, and transport of fats and sterols in the intestine and liver. Bile acids are also steroidal amphipathic molecules derived from the catabolism of cholesterol. They modulate bile flow and lipid secretion, are essential for the absorption of dietary fats and vitamins, and have been implicated in the regulation of all the key enzymes involved in cholesterol homeostasis. Bile acids recirculate through the liver, bile ducts, small intestine and portal vein to form an enterohepatic circuit. They exist as anions at physiological pH and, consequently, require a carrier for transport across the membranes of the enterohepatic tissues. The unique detergent properties of bile acids are essential for the digestion and intestinal absorption of hydrophobic nutrients. Bile acids have potent toxic properties (e.g., membrane disruption) and there are a plethora of mechanisms to limit their accumulation in blood and tissues (PMID: 11316487, 16037564, 12576301, 11907135). Glycocholic acid is found to be associated with alpha-1-antitrypsin deficiency, which is an inborn error of metabolism. Glycocholic acid is a bile acid glycine conjugate having cholic acid as the bile acid component. It has a role as a human metabolite. It is functionally related to a cholic acid and a glycochenodeoxycholic acid. It is a conjugate acid of a glycocholate. Glycocholic acid is a natural product found in Caenorhabditis elegans and Homo sapiens with data available. The glycine conjugate of CHOLIC ACID. It acts as a detergent to solubilize fats for absorption and is itself absorbed. Glycocholic acid, or cholylglycine, is a crystalline bile acid involved in the emulsification of fats. It occurs as a sodium salt in the bile of mammals. It is a conjugate of cholic acid with glycine. Its anion is called glycocholate. [Wikipedia] A bile acid glycine conjugate having cholic acid as the bile acid component. Glycocholic acid. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=475-31-0 (retrieved 2024-07-01) (CAS RN: 475-31-0). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0). Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways[1]. Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways[1].
LysoSM(d18:1)
C23H50N2O5P+ (465.34571600000004)
D-erythro-sphingosylphosphorylcholine is an intermediate in Sphingolipid metabolism. D-erythro-sphingosylphosphorylcholine is the 5th to last step in the synthesis of Digalactosylceramidesulfate and is converted from Sphingosine via the enzyme sphingosine cholinephosphotransferase ( EC 2.7.8.10). It is then converted to Sphingomyelin via the enzyme sphingosine N-acyltransferase (EC 2.3.1.24). [HMDB] D-erythro-sphingosylphosphorylcholine is an intermediate in Sphingolipid metabolism. D-erythro-sphingosylphosphorylcholine is the 5th to last step in the synthesis of Digalactosylceramidesulfate and is converted from Sphingosine via the enzyme sphingosine cholinephosphotransferase ( EC 2.7.8.10). It is then converted to Sphingomyelin via the enzyme sphingosine N-acyltransferase (EC 2.3.1.24).
3a,7b,12a-Trihydroxyoxocholanyl-Glycine
C26H43NO6 (465.30902180000004)
3a,7b,12a-Trihydroxyoxocholanyl-Glycine is an acyl glycine and a bile acid-glycine conjugate. It is a secondary bile acid produced by the action of enzymes existing in the microbial flora of the colonic environment. In hepatocytes, both primary and secondary bile acids undergo amino acid conjugation at the C-24 carboxylic acid on the side chain, and almost all bile acids in the bile duct therefore exist in a glycine conjugated form (PMID:16949895). 3a,7b,12a-Trihydroxyoxocholanyl-Glycine is a specific ketonic bile acid found in the urine of infants during the neonatal period. Bile acids are steroid acids found predominantly in bile of mammals. The distinction between different bile acids is minute, depends only on presence or absence of hydroxyl groups on positions 3, 7, and 12. [HMDB] 3a,7b,12a-Trihydroxyoxocholanyl-Glycine is an acyl glycine and a bile acid-glycine conjugate. It is a secondary bile acid produced by the action of enzymes existing in the microbial flora of the colonic environment. In hepatocytes, both primary and secondary bile acids undergo amino acid conjugation at the C-24 carboxylic acid on the side chain, and almost all bile acids in the bile duct therefore exist in a glycine conjugated form (PMID: 16949895). 3a,7b,12a-Trihydroxyoxocholanyl-Glycine is a specific ketonic bile acid found in the urine of infants during the neonatal period. Bile acids are steroid acids found predominantly in bile of mammals. The distinction between different bile acids is minute, depends only on presence or absence of hydroxyl groups on positions 3, 7, and 12.
LysoPC(14:1(9Z)/0:0)
C22H44NO7P (465.28552440000004)
LysoPC(14:1(9Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(14:1(9Z)), in particular, consists of one chain of myristoleic acid at the C-1 position. The myristoleic acid moiety is derived from milk fats. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. [HMDB] LysoPC(14:1(9Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(14:1(9Z)), in particular, consists of one chain of myristoleic acid at the C-1 position. The myristoleic acid moiety is derived from milk fats. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.
LysoPE(P-18:0/0:0)
LysoPE(P-18:0/0:0) is a phospho-ether lipid. Ether lipids are lipids in which one or more of the carbon atoms on glycerol is bonded to an alkyl chain via an ether linkage, as opposed to the usual ester linkage. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodelling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine, and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin and choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0, and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
Glycohyocholic acid
C26H43NO6 (465.30902180000004)
Glycohyocholic acid (GHCA) is a bile acid. Bile acids are steroid acids found predominantly in the bile of mammals. The distinction between different bile acids is minute, depending only on the presence or absence of hydroxyl groups on positions 3, 7, and 12. Bile acids are physiological detergents that facilitate excretion, absorption, and transport of fats and sterols in the intestine and liver. Bile acids are also steroidal amphipathic molecules derived from the catabolism of cholesterol. They modulate bile flow and lipid secretion, are essential for the absorption of dietary fats and vitamins, and have been implicated in the regulation of all the key enzymes involved in cholesterol homeostasis. Bile acids recirculate through the liver, bile ducts, small intestine and portal vein to form an enterohepatic circuit. They exist as anions at physiological pH and, consequently, require a carrier for transport across the membranes of the enterohepatic tissues. The unique detergent properties of bile acids are essential for the digestion and intestinal absorption of hydrophobic nutrients. Bile acids have potent toxic properties (e.g. membrane disruption) and there are a plethora of mechanisms to limit their accumulation in blood and tissues (PMID: 11316487, 16037564, 12576301, 11907135).
(8Z,11Z,13E,15S)-15-Hydroxyicosa-8,11,13-trienoylcarnitine
(8Z,11Z,13E,15S)-15-hydroxyicosa-8,11,13-trienoylcarnitine is an acylcarnitine. More specifically, it is an (8Z,11Z,13E,15S)-15-hydroxyicosa-8,11,13-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (8Z,11Z,13E,15S)-15-hydroxyicosa-8,11,13-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (8Z,11Z,13E,15S)-15-hydroxyicosa-8,11,13-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(8S,9Z,11E,14Z)-8-Hydroxyicosa-9,11,14-trienoylcarnitine
(8S,9Z,11E,14Z)-8-hydroxyicosa-9,11,14-trienoylcarnitine is an acylcarnitine. More specifically, it is an (8S,9Z,11E,14Z)-8-hydroxyicosa-9,11,14-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (8S,9Z,11E,14Z)-8-hydroxyicosa-9,11,14-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (8S,9Z,11E,14Z)-8-hydroxyicosa-9,11,14-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-Icosa-5,8,11-trienoylcarnitine
3-Icosa-5,8,11-trienoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxyicosa-5,8,11-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Icosa-5,8,11-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-Icosa-5,8,11-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-Icosa-8,11,14-trienoylcarnitine
3-Icosa-8,11,14-trienoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxyicosa-8,11,14-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Icosa-8,11,14-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-Icosa-8,11,14-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
9-(3,4-Dimethyl-5-pentylfuran-2-yl)nonanoylcarnitine
9-(3,4-dimethyl-5-pentylfuran-2-yl)nonanoylcarnitine is an acylcarnitine. More specifically, it is an 9-(3,4-dimethyl-5-pentylfuran-2-yl)nonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-(3,4-dimethyl-5-pentylfuran-2-yl)nonanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 9-(3,4-dimethyl-5-pentylfuran-2-yl)nonanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
11-(3,4-dimethyl-5-propylfuran-2-yl)undecanoylcarnitine
11-(3,4-dimethyl-5-propylfuran-2-yl)undecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-(3,4-dimethyl-5-propylfuran-2-yl)undecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-(3,4-dimethyl-5-propylfuran-2-yl)undecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 11-(3,4-dimethyl-5-propylfuran-2-yl)undecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
7-(5-Heptyl-3,4-dimethylfuran-2-yl)heptanoylcarnitine
7-(5-heptyl-3,4-dimethylfuran-2-yl)heptanoylcarnitine is an acylcarnitine. More specifically, it is an 7-(5-heptyl-3,4-dimethylfuran-2-yl)heptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-(5-heptyl-3,4-dimethylfuran-2-yl)heptanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-(5-heptyl-3,4-dimethylfuran-2-yl)heptanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
9-(5-Hexyl-3-methylfuran-2-yl)nonanoylcarnitine
9-(5-Hexyl-3-methylfuran-2-yl)nonanoylcarnitine is an acylcarnitine. More specifically, it is an 9-(5-hexyl-3-methylfuran-2-yl)nonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-(5-Hexyl-3-methylfuran-2-yl)nonanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 9-(5-Hexyl-3-methylfuran-2-yl)nonanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Docosahexaenoyl Histidine
N-docosahexaenoyl histidine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Docosahexaenoyl amide of Histidine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Docosahexaenoyl Histidine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Docosahexaenoyl Histidine is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
N-Eicosapentaenoyl Tyrosine
C29H39NO4 (465.28789340000003)
N-eicosapentaenoyl tyrosine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Eicosapentaenoic acid amide of Tyrosine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Eicosapentaenoyl Tyrosine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Eicosapentaenoyl Tyrosine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
N-Choloylglycine
C26H43NO6 (465.30902180000004)
Cholylglycine
C26H43NO6 (465.30902180000004)
D005765 - Gastrointestinal Agents > D002756 - Cholagogues and Choleretics D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids D013501 - Surface-Active Agents > D003902 - Detergents Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways[1]. Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways[1].
(7S,13E,16S,17R,18S,19E)-22-oxa-(12)-cytochalasa-5,13,19-triene-1,21-dione-7,17-dihydroxy-16,18-dimethyl-10-phenyl|cytochalasin Z8
C28H35NO5 (465.25151000000005)
16-Deethylindanomycin
C29H39NO4 (465.28789340000003)
Origin: Microbe, Heterocyclic compounds, Pyrans
18-methoxyeladine|6beta,16beta-dihydroxy-7,8-methylenedioxy-1alpha,14alpha,18-trimethoxy-N-ethylaconitane
1alpha,6beta-dihydroxy-7,8-methylenedioxy-14alpha,16beta,18beta-trimethoxy-N-ethylaconitane|uraphine
(6R,16S,18R,21R)-18,21-dihydroxy-16,18-dimethyl-10-phenyl[11]cytochalasa-13(E),19(E)-diene-1,7,17-trione|zygosporin D
C28H35NO5 (465.25151000000005)
(7S,13E,16S,17R,18S,19E)-22-oxa-(12)-cytochalasa-6(12),13,19-triene-1,21-dione-7,17-dihydroxy-16,18-dimethyl-10-phenyl|cytochalasin Z7
C28H35NO5 (465.25151000000005)
Thr Ala Phe Lys
C22H35N5O6 (465.25872100000004)
Ala Phe Thr Lys
C22H35N5O6 (465.25872100000004)
Glycocholic acid hydrate
C26H43NO6 (465.30902180000004)
Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways[1]. Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways[1].
glycocholate
C26H43NO6 (465.30902180000004)
Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways[1]. Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways[1].
C25H39NO7_(7E)-6-Hydroperoxy-11,12-dihydroxy-3-isobutyl-13-methoxy-4,5,8-trimethyl-3,3a,6,6a,9,10,11,12,13,14-decahydro-1H-cycloundeca[d]isoindole-1,15(2H)-dione
Glycocholic acid
C26H43NO6 (465.30902180000004)
MS2 deconvoluted using MS2Dec from all ion fragmentation data, MetaboLights identifier MTBLS1040; RFDAIACWWDREDC-FRVQLJSFSA-N_STSL_0092_Glycocholic acid_8000fmol_180416_S2_LC02_MS02_93; Spectrum acquired as described in Naz et al 2017 PMID 28641411. Preparation and submission to MassBank of North America by Chaleckis R. and Tada I. MS2 deconvoluted using CorrDec from all ion fragmentation data, MetaboLights identifier MTBLS1040; Spectrum acquired as described in Naz et al 2017 PMID 28641411. Preparation and submission to MassBank of North America by Chaleckis R. and Tada I. Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways[1]. Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways[1].
Glycohyocholic acid
C26H43NO6 (465.30902180000004)
A bile acid glycine conjugate having hyocholic acid as the bile acid component. CONFIDENCE standard compound; INTERNAL_ID 74
N-[(3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxy-24-oxocholan-24-yl]glycine
C26H43NO6 (465.30902180000004)
BA-133-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-133-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-133-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
sodium glycocholate
C26H43NO6 (465.30902180000004)
((4R)-4-((3R,5S,6R,7S,9S,10R,13R,14S,17R)-3,6,7-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)glycine
C26H43NO6 (465.30902180000004)
((R)-4-((3R,5S,7S,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)glycine
C26H43NO6 (465.30902180000004)
Ala Phe Lys Thr
C22H35N5O6 (465.25872100000004)
Ala Lys Phe Thr
C22H35N5O6 (465.25872100000004)
Ala Lys Thr Phe
C22H35N5O6 (465.25872100000004)
Ala Thr Phe Lys
C22H35N5O6 (465.25872100000004)
Ala Thr Lys Phe
C22H35N5O6 (465.25872100000004)
Phe Ala Lys Thr
C22H35N5O6 (465.25872100000004)
Phe Ala Thr Lys
C22H35N5O6 (465.25872100000004)
Phe Lys Ala Thr
C22H35N5O6 (465.25872100000004)
Phe Lys Thr Ala
C22H35N5O6 (465.25872100000004)
Phe Thr Ala Lys
C22H35N5O6 (465.25872100000004)
Phe Thr Lys Ala
C22H35N5O6 (465.25872100000004)
Gly Lys Val Tyr
C22H35N5O6 (465.25872100000004)
Gly Lys Tyr Val
C22H35N5O6 (465.25872100000004)
Gly Val Lys Tyr
C22H35N5O6 (465.25872100000004)
Gly Val Tyr Lys
C22H35N5O6 (465.25872100000004)
Gly Tyr Lys Val
C22H35N5O6 (465.25872100000004)
Gly Tyr Val Lys
C22H35N5O6 (465.25872100000004)
Lys Ala Phe Thr
C22H35N5O6 (465.25872100000004)
Lys Ala Thr Phe
C22H35N5O6 (465.25872100000004)
Lys Phe Ala Thr
C22H35N5O6 (465.25872100000004)
Lys Phe Thr Ala
C22H35N5O6 (465.25872100000004)
Lys Gly Val Tyr
C22H35N5O6 (465.25872100000004)
Lys Gly Tyr Val
C22H35N5O6 (465.25872100000004)
Lys Thr Ala Phe
C22H35N5O6 (465.25872100000004)
Lys Thr Phe Ala
C22H35N5O6 (465.25872100000004)
Lys Val Gly Tyr
C22H35N5O6 (465.25872100000004)
Lys Val Tyr Gly
C22H35N5O6 (465.25872100000004)
Lys Tyr Gly Val
C22H35N5O6 (465.25872100000004)
Lys Tyr Val Gly
C22H35N5O6 (465.25872100000004)
Pro Pro Pro Arg
C21H35N7O5 (465.26995400000004)
Pro Pro Arg Pro
C21H35N7O5 (465.26995400000004)
Pro Arg Pro Pro
C21H35N7O5 (465.26995400000004)
Arg Pro Pro Pro
C21H35N7O5 (465.26995400000004)
Thr Ala Lys Phe
C22H35N5O6 (465.25872100000004)
Thr Phe Ala Lys
C22H35N5O6 (465.25872100000004)
Thr Phe Lys Ala
C22H35N5O6 (465.25872100000004)
Thr Lys Ala Phe
C22H35N5O6 (465.25872100000004)
Thr Lys Phe Ala
C22H35N5O6 (465.25872100000004)
Val Gly Lys Tyr
C22H35N5O6 (465.25872100000004)
Val Gly Tyr Lys
C22H35N5O6 (465.25872100000004)
Val Lys Gly Tyr
C22H35N5O6 (465.25872100000004)
Val Lys Tyr Gly
C22H35N5O6 (465.25872100000004)
Val Tyr Gly Lys
C22H35N5O6 (465.25872100000004)
Val Tyr Lys Gly
C22H35N5O6 (465.25872100000004)
Tyr Gly Lys Val
C22H35N5O6 (465.25872100000004)
Tyr Gly Val Lys
C22H35N5O6 (465.25872100000004)
Tyr Lys Gly Val
C22H35N5O6 (465.25872100000004)
Tyr Lys Val Gly
C22H35N5O6 (465.25872100000004)
Tyr Val Gly Lys
C22H35N5O6 (465.25872100000004)
Tyr Val Lys Gly
C22H35N5O6 (465.25872100000004)
PC(14:1/0:0)
C22H44NO7P (465.28552440000004)
PC(14:2l8,8/0:0)[U]
C22H44NO7P (465.28552440000004)
PC(P-15:0/0:0)
ST 24:1;O5;G
C26H43NO6 (465.30902180000004)
2-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid,hydrate
C26H43NO6 (465.30902180000004)
PHOSPHOENOLPYRUVIC ACID TRIS(CYCLOHEXYLAMMONIUM) SALT
C21H44N3O6P (465.29675740000005)
Tricyclohexanaminium 2-(phosphonatooxy)acrylate
C21H44N3O6P (465.29675740000005)
Phosphoenolpyruvic acid tricyclohexylammoniu?m salt is a glycolysis metabolite with a high-energy phosphate group, penetrates the cell membrane and exhibits cytoprotective and anti-oxidative activity[1].
n-2-nitrophenylsulfenyl-l-isoleucine dicyclohexylammonium salt
C24H39N3O4S (465.26611340000005)
N-[(9R)-6-Methoxycinchonan-9-yl]-N-[(2S)-2-pyrrolidinylMethyl]-Thiourea
C26H35N5OS (465.25621800000005)
1-Azoniabicyclo(2.2.2)octane, 1-(2-(4-fluorophenyl)ethyl)-3-((2S)-1-oxo-2-phenyl-2-(1-piperidinyl)propoxy)-, (3R)-
C29H38FN2O2+ (465.29171599999995)
Olivoretin
D009676 - Noxae > D011042 - Poisons > D008235 - Lyngbya Toxins D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins
Olivoretin C
D009676 - Noxae > D011042 - Poisons > D008235 - Lyngbya Toxins D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins
1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(2-(3-hydroxypropylamino)-5,6-dimethyl-1H-benzo[d]imidazol-1-yl)ethanone
Phosphoric acid, mono(2-aminoethyl) mono[2-hydroxy-3-(1-octadecenyloxy)propyl] ester, (R)-
2-Amino-3-hydroxyoctadec-4-en-1-yl 2-(trimethylazaniumyl)ethyl phosphate
C23H50N2O5P+ (465.34571600000004)
(3-beta)-Cholest-5-en-3-ol-3-(hydrogen sulfate)
C27H45O4S- (465.30383900000004)
Olivoretin B
D009676 - Noxae > D011042 - Poisons > D008235 - Lyngbya Toxins D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins
(6S,9S,14R)-17-butyl-14-ethenyl-6-(methoxymethyl)-10,14-dimethyl-9-propan-2-yl-2,7,10-triazatetracyclo[9.7.1.04,19.013,18]nonadeca-1(18),3,11(19),12-tetraen-8-one
9-(3,4-Dimethyl-5-pentylfuran-2-yl)nonanoylcarnitine
7-(5-Heptyl-3,4-dimethylfuran-2-yl)heptanoylcarnitine
11-(3,4-dimethyl-5-propylfuran-2-yl)undecanoylcarnitine
(8S,9Z,11E,14Z)-8-Hydroxyicosa-9,11,14-trienoylcarnitine
(8Z,11Z,13E,15S)-15-Hydroxyicosa-8,11,13-trienoylcarnitine
2-[[(4E,7E,10E,13E,16E,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid
2-[[(4R)-1-oxo-4-[(3R,7R,10S,12S,13R,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentyl]amino]acetic acid
C26H43NO6 (465.30902180000004)
1-(1-Adamantyl)-3-[8-[[1-(2-furanylmethyl)-5-tetrazolyl]methyl]-8-azabicyclo[3.2.1]octan-3-yl]urea
(24S)-3alpha,7alpha,12alpha,24-tetrahydroxy-5beta-cholestan-26-oate
3alpha,7alpha,12alpha,24-tetrahydroxy-5beta-cholestan-26-oate with S configuration at C-24; major microspecies at pH 7.3.
1-(10z-Heptadecenoyl)-sn-glycero-3-phosphoethanolamine
C22H44NO7P (465.28552440000004)
3alpha-hydroxyetiocholan-17-one 3-O-(beta-D-glucuronate)
3-oxo-5alpha-androstan-17beta-yl beta-D-glucopyranosiduronate
(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-[2-(2-methoxyphenyl)ethynyl]-3-methyl-2-[[methyl(propyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
C27H35N3O4 (465.26274300000006)
(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-3-methyl-2-[[methyl(propyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
C27H35N3O4 (465.26274300000006)
[(E)-[(1R,4aR,4bS,8aS,10aS)-4b,8,8,10a-tetramethyl-1-[2-(5-oxo-1,2-dihydropyrrol-4-yl)ethyl]-1,3,4,4a,5,6,7,8a,9,10-decahydrophenanthren-2-ylidene]methyl] hydrogen sulfate
C25H39NO5S (465.25488040000005)
2-cyclopropyl-N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
C27H35N3O4 (465.26274300000006)
2-cyclopropyl-N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
C27H35N3O4 (465.26274300000006)
2-cyclopropyl-N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
C27H35N3O4 (465.26274300000006)
2-cyclopropyl-N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
C27H35N3O4 (465.26274300000006)
2-cyclopropyl-N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
C27H35N3O4 (465.26274300000006)
(2S,3S,3aR,9bR)-1-(cyclopentylmethyl)-3-(hydroxymethyl)-7-(4-methoxyphenyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
C27H35N3O4 (465.26274300000006)
2-cyclopropyl-N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
C27H35N3O4 (465.26274300000006)
2-cyclopropyl-N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
C27H35N3O4 (465.26274300000006)
(2R,3R,3aS,9bS)-1-(cyclopentylmethyl)-3-(hydroxymethyl)-7-(4-methoxyphenyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
C27H35N3O4 (465.26274300000006)
(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-[2-(2-methoxyphenyl)ethynyl]-3-methyl-2-[[methyl(propyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
C27H35N3O4 (465.26274300000006)
(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-[2-(2-methoxyphenyl)ethynyl]-3-methyl-2-[[methyl(propyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
C27H35N3O4 (465.26274300000006)
(2R,3R)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
2-methoxy-N-[(4R,7R,8S)-8-methoxy-5-(2-methoxy-1-oxoethyl)-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C23H35N3O7 (465.24748800000003)
2-methoxy-N-[(4R,7R,8R)-8-methoxy-5-(2-methoxy-1-oxoethyl)-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C23H35N3O7 (465.24748800000003)
2-methoxy-N-[(4R,7S,8S)-8-methoxy-5-(2-methoxy-1-oxoethyl)-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C23H35N3O7 (465.24748800000003)
2-cyclopropyl-1-[(1R)-2-(2-cyclopropyl-1-oxoethyl)-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]ethanone
C27H35N3O4 (465.26274300000006)
1-[(1R)-2-[cyclopentyl(oxo)methyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-2-cyclopropylethanone
C27H35N3O4 (465.26274300000006)
2-cyclopropyl-N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
C27H35N3O4 (465.26274300000006)
(2S,3S)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
2-methoxy-N-[(4S,7S,8S)-8-methoxy-5-(2-methoxy-1-oxoethyl)-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C23H35N3O7 (465.24748800000003)
2-methoxy-N-[(4S,7R,8R)-8-methoxy-5-(2-methoxy-1-oxoethyl)-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C23H35N3O7 (465.24748800000003)
2-methoxy-N-[(4S,7S,8R)-8-methoxy-5-(2-methoxy-1-oxoethyl)-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C23H35N3O7 (465.24748800000003)
2-methoxy-N-[(4R,7S,8R)-8-methoxy-5-(2-methoxy-1-oxoethyl)-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C23H35N3O7 (465.24748800000003)
2-cyclopropyl-1-[(1S)-2-(2-cyclopropyl-1-oxoethyl)-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]ethanone
C27H35N3O4 (465.26274300000006)
1-[(1S)-2-[cyclopentyl(oxo)methyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-2-cyclopropylethanone
C27H35N3O4 (465.26274300000006)
3alpha,7alpha,12alpha,24-Tetrahydroxy-5beta-cholestan-26-oate
The steroid acid anion formed by proton loss from the carboxy group of 3alpha,7alpha,12alpha,24-tetrahydroxy-5beta-cholestan-26-oic acid; major micro-species at pH 7.3.
2-[[(4R)-4-[(3R,5S,7R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid
C26H43NO6 (465.30902180000004)
2-azaniumylethyl (2R)-2-hydroxy-3-[(octadec-1-en-1-yl)oxy]propyl phosphate
17-oxo-5beta-androstan-3beta-yl beta-D-glucopyranosiduronate
[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-heptadec-10-enoate
C22H44NO7P (465.28552440000004)
2-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid
C26H43NO6 (465.30902180000004)
2-aminoethyl [2-hydroxy-3-[(Z)-octadec-9-enoxy]propyl] hydrogen phosphate
[2-hydroxy-3-[(Z)-pentadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-hydroxy-3-[(Z)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C22H44NO7P (465.28552440000004)
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-heptadec-9-enoate
C22H44NO7P (465.28552440000004)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] acetate
C22H44NO7P (465.28552440000004)
3-Hydroxy-2-(2-hydroxydodecanoylamino)undecane-1-sulfonic acid
C23H47NO6S (465.31239220000003)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] butanoate
C22H44NO7P (465.28552440000004)
3-Hydroxy-2-(2-hydroxytridecanoylamino)decane-1-sulfonic acid
C23H47NO6S (465.31239220000003)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] propanoate
C22H44NO7P (465.28552440000004)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-tridec-9-enoate
C21H40NO8P (465.24914100000007)
[1-acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] (Z)-tetradec-9-enoate
C21H40NO8P (465.24914100000007)
2-[4-[(3R,5S,7R,8R,9S,12S,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]acetic acid
C26H43NO6 (465.30902180000004)
2-[hydroxy-[(E)-3-hydroxy-2-(pentanoylamino)dodec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-acetamido-3-hydroxypentadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-(propanoylamino)tetradec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-(octanoylamino)non-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-(heptanoylamino)-3-hydroxydec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-(hexanoylamino)-3-hydroxyundec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-(nonanoylamino)oct-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-(butanoylamino)-3-hydroxytridec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
cholesterol sulfate(1-)
C27H45O4S (465.30383900000004)
A steroid sulfate oxoanion obtained by deprotonation of the sulfo group of cholesterol sulfate; major species at pH 7.3.
3a,7b,12a-Trihydroxyoxocholanyl-Glycine
C26H43NO6 (465.30902180000004)
1-(9Z-tetradecenoyl)-sn-glycero-3-phosphocholine
C22H44NO7P (465.28552440000004)
1-(1Z-octadecenyl)-sn-glycero-3-phosphoethanolamine
1-(9Z-octadecenyl)-sn-glycero-3-phosphoethanolamine
1-(9Z-heptadecenoyl)-sn-glycero-3-phosphoethanolamine
C22H44NO7P (465.28552440000004)
5alpha-dihydrotestosterone 17-O-(beta-D-glucuronide)(1-)
A steroid glucuronide anion that is the conjugate base of 5alpha-dihydrotestosterone 17-O-(beta-D-glucuronide) arising from deprotonation of the carboxylic acid function; major species at pH 7.3.
1-(octadec-1-enyl)-sn-glycero-3-phosphoethanolamine zwitterion
1-(alk-1-enyl)-sn-glycero-3-phosphoethanolamine zwitterion in which the alk-1-enyl group is specified as octadec-1-enyl.
lysophosphatidylcholine 14:1
C22H44NO7P (465.28552440000004)
A lysophosphatidylcholine in which the remaining acyl group contains 14 carbons and 1 double bond. If R1 is the acyl group and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is the acyl group then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.
lysophosphatidylcholine 14:1(9Z)/0:0
C22H44NO7P (465.28552440000004)
A lysophosphatidylcholine 14:1 in which the remaining acyl group is (9Z)-tetradecenoyl.
1-(octadec-1-enyl)-sn-glycero-3-phosphoethanolamine
1-(alk-1-enyl)-sn-glycero-3-phosphoethanolamine in which the alk-1-enyl group is specified as octadec-1-enyl.
1-[(1Z)-octadec-1-enyl]-sn-glycero-3-phosphoethanolamine
A 1-(Z-alk-1-enyl)-sn-glycero-3-phosphoethanolamine in which the Z-alk-1-enyl group is specified as (1Z)-octadec-1-enyl.
etiocholanolone 3-glucuronide(1-)
A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of etiocholanolone 3-glucuronide.
PE(16:1)
C21H40NO8P (465.24914100000007)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
LdMePE(16:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
PC(14:1)
C22H44NO7P (465.28552440000004)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
(1s,2s,3s,4s,5s,6r,8s,9r,10s,13s,16r,17r)-11-ethyl-8,9,16-trihydroxy-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
11-ethyl-4,16,18-trihydroxy-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-8-yl acetate
(6s,9s,14r,17r)-17-ethenyl-9,14-diisopropyl-6-(methoxymethyl)-10,14,17-trimethyl-2,7,10-triazatetracyclo[9.7.1.0⁴,¹⁹.0¹³,¹⁸]nonadeca-1(18),3,7,11(19),12-pentaen-8-ol
(1r,2s,3s,4s,5r,6s,8r,12s,13s,16r,19s,20r,21s)-14-ethyl-4,6,19-trimethoxy-16-methyl-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosane-2,21-diol
11-ethyl-8,9-dihydroxy-4,6,16-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-18-yl acetate
n-(3-chloro-2-{3-methyl-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-1-yl}prop-2-en-1-yl)-7-methoxy-n-methyltetradec-4-enamide
C26H40ClNO4 (465.2645710000001)
11-ethyl-8,9,16-trihydroxy-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
(1r,2s,3s,4s,5s,6s,8r,12r,13s,16s,19s,20r)-14-ethyl-6,19-dimethoxy-16-(methoxymethyl)-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosane-2,4-diol
2-hydroxy-n-{1-[2-(2-isopropyl-3-methoxy-5-oxo-2h-pyrrole-1-carbonyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}-3-methylpentanimidic acid
5-(2-{1-[2-(4-hydroxyphenyl)ethyl]-2,5-dioxopyrrol-3-yl}ethyl)-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalene-1-carboxylic acid
C28H35NO5 (465.25151000000005)
5a,8,8,11a-tetramethyl-1-oxo-3-(pyridin-3-yl)-6,7,7a,9,10,11,11b,12-octahydro-2,5-dioxatetraphen-9-yl propanoate
C28H35NO5 (465.25151000000005)
20-benzyl-6,22-dihydroxy-17,18-dimethyl-2,16-dioxa-21-azatetracyclo[12.8.0.0¹,¹⁹.0¹⁵,¹⁷]docosa-4,12,21-trien-3-one
C28H35NO5 (465.25151000000005)
(6s,9s,14s,17r)-17-ethenyl-9,14-diisopropyl-6-(methoxymethyl)-10,14,17-trimethyl-2,7,10-triazatetracyclo[9.7.1.0⁴,¹⁹.0¹³,¹⁸]nonadeca-1(18),3,7,11(19),12-pentaen-8-ol
14-benzyl-6,11,16-trihydroxy-5,7,13-trimethyl-12-methylidene-5h,6h,7h,8h,10ah,11h,13h,13ah,14h-oxacyclododeca[2,3-d]isoindol-2-one
C28H35NO5 (465.25151000000005)
18-demethoxypubescenine
{"Ingredient_id": "HBIN002104","Ingredient_name": "18-demethoxypubescenine","Alias": "NA","Ingredient_formula": "C25H39NO7","Ingredient_Smile": "CCN1CC2(CCC(C34C2C(C(C31)(C5(CC(C6CC4C5C6OC(=O)C)OC)OC)O)O)O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "5052","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
6,14-dimethoxyforesticine
C26H43NO6 (465.30902180000004)
{"Ingredient_id": "HBIN012005","Ingredient_name": "6,14-dimethoxyforesticine","Alias": "NA","Ingredient_formula": "C26H43NO6","Ingredient_Smile": "CCN1CC2(CCC(C34C2C(C(C31)C5(CC(C6CC4C5C6OC)OC)O)OC)OC)COC","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "6226","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
4-ethyl-12,14,16-trimethoxy-10-(methoxymethyl)-6-oxa-4-azaheptacyclo[15.2.1.0²,⁷.0²,¹¹.0³,¹³.0⁵,¹⁰.0¹⁴,¹⁹]icosane-13,18-diol
14-ethyl-4,6-dimethoxy-16-(methoxymethyl)-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosane-19,21-diol
[(1s,2r,3r,4s,5r,6s,8r,9r,10r,13s,16s,17r,18r)-11-ethyl-4,6,8,16,18-pentamethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methanol
C26H43NO6 (465.30902180000004)
(1s,2r,3r,4s,5r,6s,8r,12s,13s,16s,19s,20r,21s)-14-ethyl-4,6-dimethoxy-16-(methoxymethyl)-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosane-19,21-diol
(3s,3ar,4s,6s,6ar,10s,12r,15r,15ar)-3-benzyl-1,6,12,15-tetrahydroxy-4,10,12-trimethyl-5-methylidene-3h,3ah,4h,6h,6ah,9h,10h,15h-cycloundeca[d]isoindol-11-one
C28H35NO5 (465.25151000000005)
(1s,2r,3s,5r,6s,8r,9s,10s,13s,16r,17r,18s)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-one
(5s,7s,10as,11s,13as,14s,16as)-14-benzyl-5,11,16-trihydroxy-5,7,12,13-tetramethyl-6h,7h,8h,10ah,11h,13ah,14h-oxacyclododeca[2,3-d]isoindol-2-one
C28H35NO5 (465.25151000000005)
(4e,7r)-n-[(2z)-2-chloro-3-[(1r,6r)-3-methyl-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-1-yl]prop-2-en-1-yl]-7-methoxy-n-methyltetradec-4-enamide
C26H40ClNO4 (465.2645710000001)
(4ar,5s,6r,8ar)-5-(2-{1-[2-(4-hydroxyphenyl)ethyl]-2,5-dioxopyrrol-3-yl}ethyl)-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalene-1-carboxylic acid
C28H35NO5 (465.25151000000005)
14-ethyl-4,6,19-trimethoxy-16-methyl-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosane-2,21-diol
5-hydroxy-3-{[6-(2-hydroxypropan-2-yl)-8,8-dimethyl-2-(2-methylbut-3-en-2-yl)-1h,5h,6h-pyrano[4,3-f]indol-3-yl]methylidene}-6-methyl-1,6-dihydropyrazin-2-one
C27H35N3O4 (465.26274300000006)
(1s,2r,3r,4s,5r,6s,8r,9r,10s,13s,16s,17r,18s)-11,18-diethyl-13-(hydroxymethyl)-4,6,16-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9-diol
C26H43NO6 (465.30902180000004)
(3r,3as,6r,6as,10r,11s,12r,15ar)-3-benzyl-6-hydroperoxy-1,11-dihydroxy-4,5,10,12-tetramethyl-3h,3ah,6h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one
C28H35NO5 (465.25151000000005)
3-benzyl-1,12,15-trihydroxy-4,10,12-trimethyl-3h,3ah,4h,6ah,9h,10h,11h,15h-cycloundeca[d]isoindole-5-carboxylic acid
C28H35NO5 (465.25151000000005)
(3s,3ar,4s,6s,6ar,10r,14r)-3-benzyl-1,6,14-trihydroxy-4,10-dimethyl-5-methylidene-3h,3ah,4h,6h,6ah,9h,10h,11h,12h,13h,14h,15h,16h-cyclotrideca[d]isoindol-17-one
C29H39NO4 (465.28789340000003)
7,8,19-trihydroxy-2,10-dimethyl-17-(octa-2,4-dien-1-yl)-16-azatetracyclo[12.6.0.0⁴,⁹.0¹⁶,²⁰]icosa-2,5,10,12-tetraen-15-one
C29H39NO4 (465.28789340000003)
(4e,7s)-n-[(2z)-3-chloro-2-[(1s,6s)-3-methyl-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-1-yl]prop-2-en-1-yl]-7-methoxy-n-methyltetradec-4-enamide
C26H40ClNO4 (465.2645710000001)
2-hydroxy-n-{1-[2-(2-isopropyl-3-methoxy-5-oxo-2h-pyrrole-1-carbonyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}-n,3-dimethylbutanamide
(1s,2r,3r,4s,5r,6s,8r,9r,10s,13s,16s,17r)-11-ethyl-8,9-dihydroxy-4,6,16-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-18-one
(1s,2r,3r,4s,5s,6s,8r,9r,10r,13s,16s,17r,18r)-11-ethyl-4,16,18-trihydroxy-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-8-yl acetate
(5s,6r,7s,10as,11s,13s,13as,14s,16as)-14-benzyl-6,11,16-trihydroxy-5,7,13-trimethyl-12-methylidene-5h,6h,7h,8h,10ah,11h,13h,13ah,14h-oxacyclododeca[2,3-d]isoindol-2-one
C28H35NO5 (465.25151000000005)
(1r,2r,3r,4r,5r,6s,8r,9s,10s,13r,16s,17s,18s)-11-ethyl-8,16,18-trihydroxy-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
(5s,6r,7s,10as,11s,13as,14s,16as)-14-benzyl-6,11,16-trihydroxy-5,7,12,13-tetramethyl-5h,6h,7h,8h,10ah,11h,13ah,14h-oxacyclododeca[2,3-d]isoindol-2-one
C28H35NO5 (465.25151000000005)
(3s,3ar,6s,6ar,10s,12r,15r,15ar)-3-benzyl-1,6,12,15-tetrahydroxy-4,5,10,12-tetramethyl-3h,3ah,6h,6ah,9h,10h,15h-cycloundeca[d]isoindol-11-one
C28H35NO5 (465.25151000000005)
(3s,3ar,4s,6s,6ar,10s,12r,15r)-3-benzyl-1,6,12,15-tetrahydroxy-4,10,12-trimethyl-5-methylidene-3h,3ah,4h,6h,6ah,9h,10h,15h-cycloundeca[d]isoindol-11-one
C28H35NO5 (465.25151000000005)
(3s,3ar,4s,6s,6ar,10s,12r,15s,15ar)-3-benzyl-1,6,12,15-tetrahydroxy-4,10,12-trimethyl-5-methylidene-3h,3ah,4h,6h,6ah,9h,10h,15h-cycloundeca[d]isoindol-11-one
C28H35NO5 (465.25151000000005)
(1s,2r,3r,4s,5r,6s,8r,9s,10s,13r,16s,17r,18s)-11-ethyl-8,9-dihydroxy-4,6,16-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-18-yl acetate
(2r)-3-[(2,12-dimethyltridecanoyl)oxy]-2-hydroxypropyl 2-(trimethylammonio)ethylphosphonate
14-benzyl-5,11,16-trihydroxy-5,7,13-trimethyl-12-methylidene-6h,7h,8h,10ah,11h,13h,13ah,14h-oxacyclododeca[2,3-d]isoindol-2-one
C28H35NO5 (465.25151000000005)
(2e,4e)-10-[(2r,3s,4r,6r,8s,10s,11s)-4,10-dihydroxy-2,3,11-trimethyl-1-oxaspiro[5.5]undecan-8-yl]-4-ethyl-8-(hydroxymethyl)undeca-2,4-dienimidic acid
(2s)-2-hydroxy-n-[(2s)-1-[(2s)-2-[(2s)-2-isopropyl-3-methoxy-5-oxo-2h-pyrrole-1-carbonyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-n,3-dimethylbutanamide
11-ethyl-9,16,18-trihydroxy-6,8-dimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
5-hydroxy-6-methyl-3-{[2-(2-methylbut-3-en-2-yl)-5-[(2,2,5,5-tetramethyl-1,3-dioxolan-4-yl)methyl]-1h-indol-3-yl]methylidene}-1,6-dihydropyrazin-2-one
C27H35N3O4 (465.26274300000006)
11,18-diethyl-13-(hydroxymethyl)-4,6,16-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9-diol
C26H43NO6 (465.30902180000004)
14-ethyl-4,19-dimethoxy-16-(methoxymethyl)-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosane-6,21-diol
(1s,2r,3r,4s,5s,6s,8r,12s,13s,16s,19s,20r,21s)-14-ethyl-6,21-dimethoxy-16-(methoxymethyl)-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosane-4,19-diol
[(1r,2r,3r,4r,5r,6s,8r,9s,10s,13r,16r,17s,18s)-11-ethyl-4,6,8,16,18-pentamethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methanol
C26H43NO6 (465.30902180000004)
(1s,2s,3s,4r,5s,6s,8s,9s,10s,13r,16s,17r,18r)-11-ethyl-8,9,16-trihydroxy-6,18-dimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
(1s,2r,3r,4s,5r,6s,8r,12s,13s,16s,19s,20r,21s)-14-ethyl-4,19-dimethoxy-16-(methoxymethyl)-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosane-6,21-diol
14-benzyl-6,11,16-trihydroxy-5,7,12,13-tetramethyl-5h,6h,7h,8h,10ah,11h,13ah,14h-oxacyclododeca[2,3-d]isoindol-2-one
C28H35NO5 (465.25151000000005)
(1s,4e,6r,12e,14s,15s,17r,18s,19s,20s)-20-benzyl-6,22-dihydroxy-17,18-dimethyl-2,16-dioxa-21-azatetracyclo[12.8.0.0¹,¹⁹.0¹⁵,¹⁷]docosa-4,12,21-trien-3-one
C28H35NO5 (465.25151000000005)
(1s,2s,3s,4s,5r,6r,8s,12s,13s,16s,19r,20r,21r)-14-ethyl-6,21-dimethoxy-16-(methoxymethyl)-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosane-4,19-diol
(2r)-2-[(2s,5r,6r)-6-[(3e,5e)-6-[(3as,4r,5r,7ar)-4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl]-5-methyloxan-2-yl]propanoic acid
C29H39NO4 (465.28789340000003)
11-ethyl-8,9-dihydroxy-4,6,16-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-18-one
(2s,3s)-2-hydroxy-n-[(2s)-1-[(2s)-2-[(2s)-2-isopropyl-3-methoxy-5-oxo-2h-pyrrole-1-carbonyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-3-methylpentanimidic acid
(3r,6z)-3-methyl-6-{[2-(2-methylbut-3-en-2-yl)-5-{[(4r)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]methyl}-1h-indol-3-yl]methylidene}-3h-pyrazine-2,5-diol
C27H35N3O4 (465.26274300000006)
(2r)-2-[(5s,6r)-5-methyl-6-[(3e,5e)-6-[(4s,5r)-4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl]oxan-2-yl]propanoic acid
C29H39NO4 (465.28789340000003)
3-benzyl-6-hydroperoxy-1,11-dihydroxy-4,5,10,12-tetramethyl-3h,3ah,6h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one
C28H35NO5 (465.25151000000005)
n-[(1s,3as,3bs,5ar,7s,9ar,9bs,11as)-1-[(1s)-1-(dimethylamino)ethyl]-9a,11a-dimethyl-6-oxo-tetradecahydrocyclopenta[a]phenanthren-7-yl]pyridine-3-carboximidic acid
(1s,2r,3r,4s,5r,6s,8r,9r,10r,13s,16s,17r,18r)-11-ethyl-8,16,18-trihydroxy-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
(5ar,7ar,9s,11as,11br)-5a,8,8,11a-tetramethyl-1-oxo-3-(pyridin-3-yl)-6,7,7a,9,10,11,11b,12-octahydro-2,5-dioxatetraphen-9-yl propanoate
C28H35NO5 (465.25151000000005)
(5r,7r,10ar,11r,13r,13ar,14r,16ar)-14-benzyl-5,11,16-trihydroxy-5,7,13-trimethyl-12-methylidene-6h,7h,8h,10ah,11h,13h,13ah,14h-oxacyclododeca[2,3-d]isoindol-2-one
C28H35NO5 (465.25151000000005)
11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-one
(4s,6s,8s,10s,12s,13e,15e)-18-isocyano-4,6,8,10,12-pentamethoxy-13,15-dimethylnonadeca-1,13,15-triene
(5r,7s,10as,13s,13as,14s,16ar)-6,16-dihydroxy-14-[(4-hydroxyphenyl)methyl]-5,7,12,13-tetramethyl-5h,6h,7h,8h,10ah,13h,13ah,14h-oxacyclododeca[3,2-d]isoindol-2-one
C28H35NO5 (465.25151000000005)
6,16-dihydroxy-14-[(4-hydroxyphenyl)methyl]-5,7,12,13-tetramethyl-5h,6h,7h,8h,10ah,13h,13ah,14h-oxacyclododeca[3,2-d]isoindol-2-one
C28H35NO5 (465.25151000000005)
18-benzyl-7,20-dihydroxy-6,8,15,16-tetramethyl-2,14-dioxa-19-azatetracyclo[10.8.0.0¹,¹⁷.0¹³,¹⁵]icosa-4,10,19-trien-3-one
C28H35NO5 (465.25151000000005)
n-{1-[1-(dimethylamino)ethyl]-9a,11a-dimethyl-6-oxo-tetradecahydrocyclopenta[a]phenanthren-7-yl}pyridine-3-carboximidic acid
n-(2-chloro-3-{3-methyl-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-1-yl}prop-2-en-1-yl)-7-methoxy-n-methyltetradec-4-enamide
C26H40ClNO4 (465.2645710000001)
(3z,5e,7e,9e,11r,12s,13z,15e,17e,19e,21e,24s)-3-methoxy-5,11,17,21,24-pentamethyl-1-azacyclotetracosa-1,3,5,7,9,13,15,17,19,21-decaene-2,11,12-triol
C29H39NO4 (465.28789340000003)
(2r)-2-[(2r,5s,6r)-6-[(3e,5e)-6-[(3ar,4s,5r,7as)-4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl]-5-methyloxan-2-yl]propanoic acid
C29H39NO4 (465.28789340000003)
(1s,2r,3s,5r,6s,8r,9r,10s,13s,16s,17r,18s)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-one
(1r,2s,3s,7s,10r,11s,12s,13s,14r,16s,17r,18s,19r)-4-ethyl-12,16,18-trimethoxy-10-(methoxymethyl)-6-oxa-4-azaheptacyclo[15.2.1.0²,⁷.0²,¹¹.0³,¹³.0⁵,¹⁰.0¹⁴,¹⁹]icosane-13,14-diol
10-{4,10-dihydroxy-2,3,11-trimethyl-1-oxaspiro[5.5]undecan-8-yl}-4-ethyl-8-(hydroxymethyl)undeca-2,4-dienimidic acid
(1r,2s,3s,5r,7s,10r,11s,12s,13s,14r,16s,17s,18s,19r)-4-ethyl-12,14,16-trimethoxy-10-(methoxymethyl)-6-oxa-4-azaheptacyclo[15.2.1.0²,⁷.0²,¹¹.0³,¹³.0⁵,¹⁰.0¹⁴,¹⁹]icosane-13,18-diol
(3s,6z)-3-methyl-6-{[2-(2-methylbut-3-en-2-yl)-5-{[(4r)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]methyl}-1h-indol-3-yl]methylidene}-3h-pyrazine-2,5-diol
C27H35N3O4 (465.26274300000006)
(1r,2r,3s,5r,6s,8r,9r,10r,13r,16r,17s,18s)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-one
(3z,6s)-3-{[(6r)-6-(2-hydroxypropan-2-yl)-8,8-dimethyl-2-(2-methylbut-3-en-2-yl)-1h,5h,6h-pyrano[4,3-f]indol-3-yl]methylidene}-6-methyl-6h-pyrazine-2,5-diol
C27H35N3O4 (465.26274300000006)
(1s,3r)-1-(2-{6-[(2,2-diphenylethyl)amino]-9-methylpurin-2-yl}ethynyl)-3-methylcyclohexan-1-ol
{11-ethyl-4,6,8,16,18-pentamethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}methanol
C26H43NO6 (465.30902180000004)
17-benzyl-2,5,19-trihydroxy-5,7,14,15-tetramethyl-13-oxa-18-azatetracyclo[9.8.0.0¹,¹⁶.0¹²,¹⁴]nonadeca-3,9,18-trien-6-one
C28H35NO5 (465.25151000000005)
(3s,3ar,4s,5r,6ar,10s,12r,15r,15ar)-3-benzyl-1,12,15-trihydroxy-4,5,10,12-tetramethyl-3h,3ah,4h,5h,6ah,9h,10h,15h-cycloundeca[d]isoindole-6,11-dione
C28H35NO5 (465.25151000000005)
14-ethyl-6,19-dimethoxy-16-(methoxymethyl)-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosane-2,4-diol
[(1r,2e,4ar,4bs,8as,10as)-1-[2-(2-hydroxy-5h-pyrrol-3-yl)ethyl]-4b,8,8,10a-tetramethyl-decahydrophenanthren-2-ylidene]methoxysulfonic acid
C25H39NO5S (465.25488040000005)
2-(5-methyl-6-{6-[4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl}oxan-2-yl)propanoic acid
C29H39NO4 (465.28789340000003)
(6s,9s,14r,17r)-17-tert-butyl-14-ethenyl-9-isopropyl-6-(methoxymethyl)-10,14-dimethyl-2,7,10-triazatetracyclo[9.7.1.0⁴,¹⁹.0¹³,¹⁸]nonadeca-1(18),3,7,11(19),12-pentaen-8-ol
(3r,3as,4r,6ar,10r,12s,15s,15ar)-3-benzyl-1,12,15-trihydroxy-4,10,12-trimethyl-3h,3ah,4h,6ah,9h,10h,11h,15h-cycloundeca[d]isoindole-5-carboxylic acid
C28H35NO5 (465.25151000000005)
(2r,3z,5r,7s,9z,11r,12s,14r,15s,16r,17s)-17-benzyl-2,5,19-trihydroxy-5,7,14,15-tetramethyl-13-oxa-18-azatetracyclo[9.8.0.0¹,¹⁶.0¹²,¹⁴]nonadeca-3,9,18-trien-6-one
C28H35NO5 (465.25151000000005)
11-hydroxy-7-(2-hydroxypropan-2-yl)-5-methoxy-1,2-dimethyl-6-oxa-23-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁶,²⁴.0¹⁷,²²]tetracosa-9,16(24),17,19,21-pentaen-8-one
C28H35NO5 (465.25151000000005)
4-amino-7-carbamimidamido-2,3-dihydroxy-n-[1-(8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl)-3-methylbutyl]heptanimidic acid
C22H35N5O6 (465.25872100000004)
(2s,3as,6s,9ar,10ar)-7'-[(2s)-3,3-dimethyloxirane-2-carbonyl]-1,1,6-trimethyl-3a-(methylamino)-4,6,7,8,9,9a,10,10a-octahydro-3h-spiro[cyclopenta[b]quinolizine-2,3'-indol]-2'-ol
3-benzyl-1,6,12,15-tetrahydroxy-4,10,12-trimethyl-5-methylidene-3h,3ah,4h,6h,6ah,9h,10h,15h-cycloundeca[d]isoindol-11-one
C28H35NO5 (465.25151000000005)
(4e,10e)-18-benzyl-7,20-dihydroxy-6,8,15,16-tetramethyl-2,14-dioxa-19-azatetracyclo[10.8.0.0¹,¹⁷.0¹³,¹⁵]icosa-4,10,19-trien-3-one
C28H35NO5 (465.25151000000005)
2-amino-n-[4-amino-3-({3-amino-6-[(ethylamino)methyl]oxan-2-yl}oxy)-2-hydroxy-6-methoxycyclohexyl]-n-methylacetamide; carbonic acid
(2e,4e)-10-[(2r,3s,4r,6r,8r,10s,11s)-4,10-dihydroxy-2,3,11-trimethyl-1-oxaspiro[5.5]undecan-8-yl]-4-ethyl-8-(hydroxymethyl)undeca-2,4-dienimidic acid
(1s,2e,4r,7r,8s,9s,10e,12z,14s,17r,19s,20r)-7,8,19-trihydroxy-2,10-dimethyl-17-[(2e,4e)-octa-2,4-dien-1-yl]-16-azatetracyclo[12.6.0.0⁴,⁹.0¹⁶,²⁰]icosa-2,5,10,12-tetraen-15-one
C29H39NO4 (465.28789340000003)
(1s,2r,5s,7r,11s,14s)-11-hydroxy-7-(2-hydroxypropan-2-yl)-5-methoxy-1,2-dimethyl-6-oxa-23-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁶,²⁴.0¹⁷,²²]tetracosa-9,16(24),17,19,21-pentaen-8-one
C28H35NO5 (465.25151000000005)
(1s,2r,3r,4s,5r,6s,8r,9s,10s,13r,16s,17r,18r)-11-ethyl-9,16,18-trihydroxy-6,8-dimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
(1r,4s,5s,6s,8r,9s,10s,13s,16s,18s)-11-ethyl-8,16-dihydroxy-4,6,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl acetate
(4s,6s,8s,10s,12s,13e,15e,18s)-18-isocyano-4,6,8,10,12-pentamethoxy-13,15-dimethylnonadeca-1,13,15-triene
(1s,2r,3r,4s,5r,6s,8r,9r,10s,13s,16s,17r)-11-ethyl-8,9,16-trihydroxy-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
11-ethyl-8,16,18-trihydroxy-6-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
14-benzyl-5,11,16-trihydroxy-5,7,12,13-tetramethyl-6h,7h,8h,10ah,11h,13ah,14h-oxacyclododeca[2,3-d]isoindol-2-one
C28H35NO5 (465.25151000000005)